jRCT2071210075招募中不适用
OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 主要终点
- Remission by central read Mayo score following 44 weeks in the maintenance phase
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 2age old over 至 17age old under（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •Evidence of a personally signed and dated informed consent document and assent document.
- •Males and females 2 to less than18 years old and weighing at least 10 kg.
- •Having a pathology report that confirms colonic inflammation consistent with UC with a clinical diagnosis of UC for at least 12 weeks prior to baseline, with biopsy report supporting the diagnosis of UC.
- •Participants diagnosed with UC at age less than 6 years old, must have had testing and be negative for monogenic disorders associated with very early onset IBD.
- •Moderately to severely active UC as defined (via screening colonoscopy) by a Mayo score of at least 6, with a rectal bleeding score of at least 1 and an endoscopic subscore of at least
- •Pediatric Ulcerative Colitis Activity Index (PUCAI) score greater or equal to 35 .
- •No history of dysplasia or colon cancer.
- •No evidence or history of untreated or inadequately treated active or latent infection with Mycobacterium Tuberculosis.
- •For participants outside of the United States: have had an inadequate response or been intolerant to at least one prior therapy as listed below or have a medical contraindication to such therapies:
- •Oral or intravenous (IV) corticosteroids;
- •Azathioprine or 6-mercaptopurine;
- •TNF inhibitors or anti integrin therapy.
- •For participants in the United States: have had an inadequate response or intolerance to TNF inhibitors.
- •Stable doses of the following therapies for UC:
- •Oral 5 Aminosalicyclic acids (ASA) or sulfasalazine
- •Oral corticosteroids equivalent to prednisone at most 1 mg/kg up to a maximum of 20 mg/day or budesonide up to 9 mg/day.
- •evidence of prior varicella zoster virus exposure based on serological testing.
- •female participant is eligible if she is not pregnant or breastfeeding, If she is a woman of child bearing potential, she needs to be using a contraceptive method that is highly effective (with a failure rate of <1% per year).
排除标准
- •Exclusion Criteria:
- •Diagnosis of indeterminate colitis, isolated proctitis, microscopic colitis, infectious colitis, Crohn's disease, or clinical findings suggestive of Crohn's disease.
- •History of symptomatic obstructive intestinal strictures or active ostomy, or history of colectomy, extensive small bowel resection ( greater than100 centimetres) or short bowel syndrome, or hospitalization for UC related reason(s) within 4 weeks of baseline visit.
- •Any factors or clinical characteristics potentially related to the risk of venous thromboembolism that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- •Participants who have previously received tofacitinib or another Janus Kinase inhibitor.
- •Vaccination or exposure to a live or attenuated vaccine within the 6 weeks prior to the first dose of study drug, or who are expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study drug.
- •Participants having received azathioprine, 6-mercaptopurine, methotrexate, thioguanine, infliximab, adalimumab, golimumab, interferon, cyclosporine, mycophenolate, tacrolimus, IV or rectally administered corticosteroids, natalizumab, vedolizumab, other antiadhesion molecules, or investigational drugs during the specified time periods prior to baseline whereby they may still have pharmacokinetic and/or pharmacodynamic effect in the body of the participant.
- •Previous treatment by leukocyte apheresis including selective lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange within 6 months prior to baseline.
- •Treatment by specified prohibited concomitant medications, including moderate to potent CYP3A inducers or inhibitors in the specified time periods prior to the first dose of study drug or are expected to receive any of these medications during the study period.
- •Chronic and frequent use of antimotility agents for control of diarrhea (ie, diphenoxylate hydrochloride with atropine sulfate or loperamide).
- •History of bowel surgery, including cholecystectomy within 6 months prior to baseline, history of appendectomy within 3 months prior to baseline, or significant trauma or major surgery within 4 weeks of screening visit are excluded.
- •Participants with the following laboratory values at screening:
- •Hemoglobin level lower than 9.0 g/Dl.
- •Absolute white blood cell (WBC) count lower than 3000/mm
- •Absolute neutrophil count lower than 1200/mm
- •Absolute lymphocyte count lower than 750/mm
- •Thrombocytopenia as defined by a platelet count lower than 100,000/mm
- •Estimated bedside Schwartz Glomerular filtration rate (GFR) lower or equal to 40 mL/min/1.73 m
- •Total bilirubin, aspartate aminostransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal.
- •Positive stool examinations for enteric pathogens, pathogenic ova or parasites, or C. difficile toxin at screening.
- •Participants infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses.
- •History of more than one episode of HZ, a history of disseminated HZ or disseminated herpes simplex.
- •History or current symptoms of any lymphoproliferative disorder (eg, Epstein Barr Virus (EBV) related lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorders, multiple myeloma, or signs and symptoms suggestive of currently lymphatic disease).
- •Clinically significant infections currently or within 3 months prior to baseline (eg, those requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections), a history of any infection requiring antimicrobial therapy within 2 weeks of baseline, or a history of any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
- •Any malignancies or with a history of malignancies, with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin.
- •Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees of the Sponsor, including their family members, directly involved in the conduct of the study.
- •Participation in other studies involving investigational drug(s) within 2 months prior to study entry and/or during study participation.
- •Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- •Pregnant female participants; breastfeeding female participants; fertile female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and through the telephone follow up visit.
结局指标
主要结局
Remission by central read Mayo score following 44 weeks in the maintenance phase
时间窗: Outcome measured at the end of the 44 weeks of the maintenance phase
Remission is defined by central endoscopy read Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The primary outcome Mayo score is the summation of 4 subscores as listed below: * patient reported stool frequency (scored 0 to 3) * patient reported rectal bleeding (scored 0 to 3) * central read findings on endoscopy (scored 0 to 3) * physician's global assessment (scored 0 to 3) The Mayo score has a scale from 0 to 12 points, with the lower score indicating lower ulcerative colitis (UC) disease activity.
次要结局
未报告次要终点
研究者
相似试验
尚未招募
Unknown
A clinical trial to Study the effects of oral tofacitinib and azathioprine in chronic actinic dermatitisCTRI/2023/03/051181Krishna Vishwa Vidyapeeth
尚未招募
Unknown
A comparison of efficacy and safety of oral tofacitinib vs methotrexate in management of moderate to severe chronic plaque psoriasisCTRI/2023/06/053443one
招募中
2 期
TiNT: Trametinib in Neurofibromatosis type 1 associated tumoursPlexiform neurofibromatosisOptic pathway gliomaCancer - Children's - BrainCancer - Children's - OtherHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersNeurological - Other neurological disordersNeurofibromatosis type 1ACTRN12620001229965Australian and New Zealand Children's Haematology/Oncology Group120
Enrolling By Invitation
4 期
Efficacy and Safety of Tofacitinib in Refractory Blau SyndromeBlau SyndromeNCT06660329Peking Union Medical College Hospital30
招募中
1 期
Effects of Tofacitinib on Ulcerative Colitis patientslcerative Colitis.Ulcerative colitisIRCT20181217042020N2Digestive Disease Research Institute of Tehran University of Medical Sciences40